Pregnancy and obstetrics. Recombinant versus urinary FSH for ovarian stimulation in assisted reproduction

By Ola Bolarinde   Afnan Masoud   Hammadieh Nahed  

Human Reproduction, Vol. 15, Iss. 5, 2000-05 ,pp. : 1208-1209

Oxford University Press

Access to resources Recommend Favorite

Endocrinology. A prospective, randomized clinical trial comparing 150 IU recombinant follicle stimulating hormone (Puregon ® ) and 225 IU highly purified urinary follicle stimulating hormone (Metrodin-HP ® ) in a fixed-dose regimen in women undergoing ovarian stimulation

By Hoomans Eric H.M.  

Human Reproduction, Vol. 14, Iss. 10, 1999-10 ,pp. : 2442-2447

Oxford University Press

Access to resources Recommend Favorite

Endocrinology. Increasing the daily dose of recombinant follicle stimulating hormone (Puregon ® ) does not compensate for the age-related decline in retrievable oocytes after ovarian stimulation

By Out Henk J.  

Human Reproduction, Vol. 15, Iss. 1, 2000-01 ,pp. : 29-35

Oxford University Press

Access to resources Recommend Favorite

Endocrinology. Recombinant human follicle stimulating hormone versus human menopausal gonadotrophin induction: effects in mature follicle endocrinology

By Teissier M.P.  

Human Reproduction, Vol. 14, Iss. 9, 1999-09 ,pp. : 2236-2241

Oxford University Press

Access to resources Recommend Favorite

Pregnancy and obstetrics. Meta-analysis on recombinant versus urinary follicle stimulating hormone

By  

Human Reproduction, Vol. 15, Iss. 7, 2000-07 ,pp. : 1650-1651

Oxford University Press

Access to resources Recommend Favorite